Pyxis Oncology, a Boston-based biotech company, has raised $152 million in a Series B financing round co-led by Arix Bioscience and RTW Investments. The company is developing antibody-drug conjugates (ADCs), immunotherapies, and other biologics for the treatment of difficult-to-treat cancers. Pyxis Oncology’s Series B round also saw the participation of additional new investors – Perceptive […]
Olema Oncology, a California-based biopharma company focused on developing targeted therapies for women’s cancers, has raised $54 million in a Series B financing round, which was co-led by BVF Partners, Logos Capital, and Janus Henderson Investors. The US biopharma company will use the proceeds for advancing OP-1250, its lead drug candidate in breast cancer, into […]
Protagonist Therapeutics, a clinical-stage biopharmaceutical company specializing in the discovery and development of novel peptide-based drugs, has successfully raised $22 million in new equity financing. This significant financial injection comes from BVF Partners and their affiliates, aimed at propelling the development of cutting-edge treatments for patients with substantial unmet medical needs. In this financing round, […]